In fact, TGF-β signaling blockade by some modalities [i.e., over- expression of either a dominant-negative form of TGF-β receptor type II (50) or SMAD7 (51) in breast cancer cells (52, 53) was shown to be effective in reducing bone metastases. This evidence concerns the gene TGFB1 and breast cancer.